A Phase 1 Study of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast Cancer

Study identifier:D8530C00006

ClinicalTrials.gov identifier:NCT04541433

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast Cancer

Medical condition

ER+ HER2- Advanced Breast Cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD9833

Sex

Female

Actual Enrollment

10

Study type

Interventional

Age

20 Years - 130 Years

Date

Study Start Date: 29 Sept 2020
Primary Completion Date: 29 Jul 2022
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria